Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesLiabilities and Shareholders EquityNon-Current AssetsOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPreferred Stock LiabilitiesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesReceivables - NetRetained EarningsShareholder's EquityShort-term InvestmentsTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Enanta Pharmaceuticals (ENTA) Common Equity: 2012-2025

Historic Common Equity for Enanta Pharmaceuticals (ENTA) over the last 13 years, with Sep 2025 value amounting to $64.7 million.

  • Enanta Pharmaceuticals' Common Equity fell 49.76% to $64.7 million in Q3 2025 from the same period last year, while for Sep 2025 it was $64.7 million, marking a year-over-year decrease of 49.76%. This contributed to the annual value of $64.7 million for FY2025, which is 49.76% down from last year.
  • Latest data reveals that Enanta Pharmaceuticals reported Common Equity of $64.7 million as of Q3 2025, which was down 18.37% from $79.3 million recorded in Q2 2025.
  • Enanta Pharmaceuticals' Common Equity's 5-year high stood at $436.0 million during Q1 2021, with a 5-year trough of $64.7 million in Q3 2025.
  • In the last 3 years, Enanta Pharmaceuticals' Common Equity had a median value of $148.9 million in 2024 and averaged $155.4 million.
  • Data for Enanta Pharmaceuticals' Common Equity shows a maximum YoY slumped of 49.76% (in 2025) over the last 5 years.
  • Over the past 5 years, Enanta Pharmaceuticals' Common Equity (Quarterly) stood at $384.4 million in 2021, then decreased by 21.74% to $300.8 million in 2022, then slumped by 36.22% to $191.9 million in 2023, then tumbled by 41.73% to $111.8 million in 2024, then plummeted by 49.76% to $64.7 million in 2025.
  • Its Common Equity was $64.7 million in Q3 2025, compared to $79.3 million in Q2 2025 and $93.5 million in Q1 2025.